Several cases of stent strut fractures (SSFs) have recently been reported following drug-eluting stent (DES) implantation Although SSF is a rare complication, it has been suggested to be a cause of restenosis. To date, a number of cases of stent fracture have been associated with sirolimus-eluting stents and they occurred from 2 days to about 2 years after the initial procedure. We report here on a case of paclitaxel-eluting stent fracture at the time of stent placement in a calcified coronary lesion.
Drug-Eluting Stents ; Stents

No abstract available.
Drug-Eluting Stents ; Stents

The development of drug eluting-stents has been a breakthrough for the prevention of PCI postoperative restenosis, and the correlative researches have not yet stopped and are still the focus of the world. We review, in this article, the history of drug eluting-stents researches, analyze the research actualities and the problems existing, and forecast the developing trend in the future.
Drug-Eluting Stents ; trends

No abstract available.
Drug-Eluting Stents

No abstract available.
Drug-Eluting Stents* ; Ultrasonography*

No abstract available.
Dilatation* ; Drug-Eluting Stents* ; Stents*

Coronary stent thrombosis (ST) has been regarded as a rare but catastrophic complication of bare-metal stent (BMS) implantation that normally occurs during the first few weeks after stenting. In the drug-eluting stent (DES) era, there has been increasing concern regarding higher rates of ST due to delayed endothelialization. However, a pooled meta-analysis of randomized clinical trials and registry studies showed rates of ST (0.4-1.5%) after DES to be similar to those of BMS. The rate of ST did not differ between sirolimus- and paclitaxel-eluting stents. Additionally, the rates of late ST were similar between DES and BMS. Remarkably, very late occurrence of ST, which develops up to 1-2 years after DES implantation, was significantly associated with complete cessation of antiplatelet therapy. Further large-scale studies are needed to determine the optimal combination and duration for antiplatelet therapy in order to prevent these serious thrombotic events.
Drug-Eluting Stents* ; Stents* ; Thrombosis*

No abstract available.
Drug-Eluting Stents ; Humans ; Stents

Endoscopic stenting is increasingly being used in the management of gastrointestinal luminal obstruction, and has become the current treatment of choice for the palliation of blockage caused by malignant or benign growths. A variety of stents have been developed to enhance the efficacy of the procedure, and improvements are ongoing. In this article, we review the history of, and recent advances in, gastrointestinal stenting. We describe the rationale behind the design as well as the resulting outcome for each stent type.
Drug-Eluting Stents ; Endoscopy, Gastrointestinal ; Phenobarbital ; Stents*

Endoscopic stenting is increasingly being used in the management of gastrointestinal luminal obstruction, and has become the current treatment of choice for the palliation of blockage caused by malignant or benign growths. A variety of stents have been developed to enhance the efficacy of the procedure, and improvements are ongoing. In this article, we review the history of, and recent advances in, gastrointestinal stenting. We describe the rationale behind the design as well as the resulting outcome for each stent type.
Drug-Eluting Stents ; Endoscopy, Gastrointestinal ; Phenobarbital ; Stents*